Citation: | Zhu Ping, Shan Xia, Liu Jinhui, Zhou Xin, Zhang Huo, Wang Tongshan, Wu Jianqing, Zhu Wei, Liu Ping. miR-3622b-5p regulates cisplatin resistance of human gastric cancer cell line by targeting BIRC5[J]. The Journal of Biomedical Research, 2019, 33(6): 382-390. DOI: 10.7555/JBR.33.20180078 |
[1] |
Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012[J]. Int J Cancer, 2015, 136(5): E359–E386. doi: 10.1002/ijc.29210
|
[2] |
Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer[J]. N Engl J Med, 2006, 355(1): 11–20. doi: 10.1056/NEJMoa055531
|
[3] |
Hwang JH. Understanding gastric cancer risk factors: we need to close the gap[J]. Gut Liver, 2018, 12(1): 1–2. doi: 10.5009/gnl17503
|
[4] |
Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14[J]. Cell, 1993, 75(5): 843–854. doi: 10.1016/0092-8674(93)90529-Y
|
[5] |
Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function[J]. Cell, 2004, 116(2): 281–297. doi: 10.1016/S0092-8674(04)00045-5
|
[6] |
Zhao HN, Yu XT, Ding YF, et al. MiR-770-5p inhibits cisplatin chemoresistance in human ovarian cancer by targeting ERCC2[J]. Oncotarget, 2016, 7(33): 53254–53268.
|
[7] |
Wang L, Chen Y, Jiang Y, et al. MiR-199a-3p affects the multi-chemoresistance of osteosarcoma through targeting AK4[J]. BMC Cancer, 2018, 18(1): 631. doi: 10.1186/s12885-018-4460-0
|
[8] |
Huang LM, Hu CQ, Cao H, et al. MicroRNA-29c increases the chemosensitivity of pancreatic cancer cells by inhibiting USP22 mediated autophagy[J]. Cell Physiol Biochem, 2018, 47(2): 747–758. doi: 10.1159/000490027
|
[9] |
Wang M, Cai WR, Meng R, et al. miR-485-5p suppresses breast cancer progression and chemosensitivity by targeting survivin[J]. Biochem Biophys Res Commun, 2018, 501(1): 48–54. doi: 10.1016/j.bbrc.2018.04.129
|
[10] |
Lu MJ, Wang TS, He MF, et al. Tumor suppressor role of miR-3622b-5p in ERBB2-positive cancer[J]. Oncotarget, 2017, 8(14): 23008–23019.
|
[11] |
Qiu TZ, Zhou X, Wang J, et al. MiR-145, miR-133a and miR-133b inhibit proliferation, migration, invasion and cell cycle progression via targeting transcription factor Sp1 in gastric cancer[J]. FEBS Lett, 2014, 588(7): 1168–1177. doi: 10.1016/j.febslet.2014.02.054
|
[12] |
Zhao DS, Chen Y, Jiang H, et al. Serum miR-210 and miR-30a expressions tend to revert to fetal levels in Chinese adult patients with chronic heart failure[J]. Cardiovasc Pathol, 2013, 22(6): 444–450. doi: 10.1016/j.carpath.2013.04.001
|
[13] |
Zhou X, Zhu W, Li H, et al. Diagnostic value of a plasma microRNA signature in gastric cancer: a microRNA expression analysis[J]. Sci Rep, 2015, 5: 11251. doi: 10.1038/srep11251
|
[14] |
Zhu W, Shan X, Wang TS, et al. miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines[J]. Int J Cancer, 2010, 127(11): 2520–2529. doi: 10.1002/ijc.25260
|
[15] |
Zhu W, Xu HG, Zhu DX, et al. miR-200bc/429 cluster modulates multidrug resistance of human cancer cell lines by targeting BCL2 and XIAP[J]. Cancer Chemother Pharmacol, 2012, 69(3): 723–731. doi: 10.1007/s00280-011-1752-3
|
[16] |
Xia L, Zhang DX, Du R, et al. miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells[J]. Int J Cancer, 2008, 123(2): 372–379. doi: 10.1002/ijc.23501
|
[17] |
Zhu DX, Zhu W, Fang C, et al. miR-181a/b significantly enhances drug sensitivity in chronic lymphocytic leukemia cells via targeting multiple anti-apoptosis genes[J]. Carcinogenesis, 2012, 33(7): 1294–1301. doi: 10.1093/carcin/bgs179
|
[18] |
Holohan C, van Schaeybroeck S, Longley DB, et al. Cancer drug resistance: an evolving paradigm[J]. Nat Rev Cancer, 2013, 13(10): 714–726. doi: 10.1038/nrc3599
|
[19] |
Hayes JD, Wolf CR. Molecular mechanisms of drug resistance[J]. Biochem J, 1990, 272(2): 281–295. doi: 10.1042/bj2720281
|
[20] |
Sharma SV, Lee DY, Li BH, et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations[J]. Cell, 2010, 141(1): 69–80. doi: 10.1016/j.cell.2010.02.027
|
[21] |
Fojo T. Multiple paths to a drug resistance phenotype: mutations, translocations, deletions and amplification of coding genes or promoter regions, epigenetic changes and microRNAs[J]. Drug Resist Updat, 2007, 10(1–2): 59–67.
|
[22] |
Helleday T, Petermann E, Lundin C, et al. DNA repair pathways as targets for cancer therapy[J]. Nat Rev Cancer, 2008, 8(3): 193–204. doi: 10.1038/nrc2342
|
[23] |
Selvakumaran M, Pisarcik DA, Bao RD, et al. Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines[J]. Cancer Res, 2003, 63(6): 1311–1316.
|
[24] |
Liu HN, Peng Q, Yang G, et al. miR-181b inhibits chemoresistance in cisplatin-resistant H446 small cell lung cancer cells by targeting Bcl-2[J]. Arch Med Sci, 2018, 14(4): 745–751.
|
[25] |
Gao JL, Wu N, Liu XH, et al. MicroRNA-142-3p inhibits cell proliferation and chemoresistance in ovarian cancer via targeting sirtuin 1[J]. Exp Ther Med, 2018, 15(6): 5205–5214.
|
[26] |
Feng Q, He P, Wang Y. MicroRNA-223-3p regulates cell chemo-sensitivity by targeting FOXO3 in prostatic cancer[J]. Gene, 2018, 658: 152–158. doi: 10.1016/j.gene.2018.03.013
|
[27] |
Chen X, Duan N, Zhang CG, et al. Survivin and tumorigenesis: molecular mechanisms and therapeutic strategies[J]. J Cancer, 2016, 7(3): 314–323. doi: 10.7150/jca.13332
|
[28] |
Xiong CH, Liu HP, Chen ZX, et al. Prognostic role of survivin in renal cell carcinoma: a system review and meta-analysis[J]. Eur J Intern Med, 2016, 33: 102–107. doi: 10.1016/j.ejim.2016.06.009
|
[29] |
Peery RC, Liu JY, Zhang JT. Targeting survivin for therapeutic discovery: past, present, and future promises[J]. Drug Discov Today, 2017, 22(10): 1466–1477. doi: 10.1016/j.drudis.2017.05.009
|
[30] |
Nabilsi NH, Broaddus RR, Loose DS. DNA methylation inhibits p53-mediated survivin repression[J]. Oncogene, 2009, 28(19): 2046–2050. doi: 10.1038/onc.2009.62
|
[31] |
Huang JC, Lyu H, Wang JX, et al. MicroRNA regulation and therapeutic targeting of survivin in cancer[J]. Am J Cancer Res, 2015, 5(1): 20–31.
|
[1] | Pavan Kumar Dhanyamraju. Drug resistance mechanisms in cancers: Execution of pro-survival strategies[J]. The Journal of Biomedical Research, 2024, 38(2): 95-121. DOI: 10.7555/JBR.37.20230248 |
[2] | Juan Zhou, Yiran Xu, Luyao Wang, Yu Cong, Ke Huang, Xinxing Pan, Guangquan Liu, Wenqu Li, Chenchen Dai, Pengfei Xu, Xuemei Jia. LncRNA IDH1-AS1 sponges miR-518c-5p to suppress proliferation of epithelial ovarian cancer cell by targeting RMB47[J]. The Journal of Biomedical Research, 2024, 38(1): 51-65. DOI: 10.7555/JBR.37.20230097 |
[3] | Liting Lv, Xin Hua, Jiaxin Liu, Sutong Zhan, Qianqian Zhang, Xiao Liang, Jian Feng, Yong Song. Anlotinib reverses osimertinib resistance via inhibiting epithelial-to-mesenchymal transition and angiogenesis in non-small cell lung cancer[J]. The Journal of Biomedical Research. DOI: 10.7555/JBR.38.20240045 |
[4] | Yue Xiao, Yue Peng, Chi Zhang, Wei Liu, Kehan Wang, Jing Li. hucMSC-derived exosomes protect ovarian reserve and restore ovarian function in cisplatin treated mice[J]. The Journal of Biomedical Research, 2023, 37(5): 382-393. DOI: 10.7555/JBR.36.20220166 |
[5] | Haozhe Xu, Yiming Zhou, Jing Guo, Tao Ling, Yujie Xu, Ting Zhao, Chuanxin Shi, Zhongping Su, Qiang You. Elevated extracellular calcium ions accelerate the proliferation and migration of HepG2 cells and decrease cisplatin sensitivity[J]. The Journal of Biomedical Research, 2023, 37(5): 340-354. DOI: 10.7555/JBR.37.20230067 |
[6] | Xiao Shi, Xinxin Si, Ershao Zhang, Ruochen Zang, Nan Yang, He Cheng, Zhihong Zhang, Beijing Pan, Yujie Sun. Paclitaxel-induced stress granules increase LINE-1 mRNA stability to promote drug resistance in breast cancer cells[J]. The Journal of Biomedical Research, 2021, 35(6): 411-424. DOI: 10.7555/JBR.35.20210105 |
[7] | Min-Young Kim, Woon-Dong Cho, Kwon Pyo Hong, Da Bin Choi, Jeong won Hong, Soseul Kim, Yoo Ri Moon, Seung-Myoung Son, Ok-Jun Lee, Ho-Chang Lee, Hyung Geun Song. Novel monoclonal antibody against beta 1 integrin enhances cisplatin efficacy in human lung adenocarcinoma cells[J]. The Journal of Biomedical Research, 2016, 30(3): 217-224. DOI: 10.7555/JBR.30.2016K0005 |
[8] | Xiaoyan Wang, Guozhu Wang, Yi Zhao, Xiaoan Liu, Qiang Ding, Jingping Shi, Yin Ding, Shui Wang. STAT3 mediates resistance of CD44+CD24-/low breast cancer stem cells to tamoxifen in vitro[J]. The Journal of Biomedical Research, 2012, 26(5): 325-335. DOI: 10.7555/JBR.26.20110050 |
[9] | Li Liu, Qi Chen, Rensheng Lai, Xiaobin Wu, Xiaoyu Wu, Fukun Liu, Guohua Xu, Yong Ji. Elevated expression of mature miR-21 and miR-155 in cancerous gastric tissues from Chinese patients with gastric cancer[J]. The Journal of Biomedical Research, 2010, 24(3): 187-197. |
[10] | Daozhen Chen, Qiusha Tang, Wenqun Xue, Jingying Xiang, Li Zhang, Xinru Wang. The preparation and characterization of folate-conjugated human serum albumin magnetic cisplatin nanoparticles[J]. The Journal of Biomedical Research, 2010, 24(1): 26-32. |